After a second death was reported for a patient using Sarepta’s (SRPT) Elevidys, BofA says the firm expects that immune prophylaxis will be in the spotlight with Sarepta planning to explore use of sirolimus in non-ambulatory patients. Immune suppression has been implemented by Regenxbio (RGNX) from the beginning, potentially contributing to superior safety for RGX-202 observed to date, adds the analyst, who expects no changes for RGX-202 after the competitor safety issue. The firm, which sees “a clear path to market” for RGX-202, maintains a Buy rating and $22 price target on Regenxbio shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio files to sell 268,096 shares of common stock for holders
- Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism
- Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio’s RGX-202
- RegenXBio: Promising Gene Therapy Developments and Strong Financial Position Support Buy Rating
- Regenxbio’s RGX-202 shows efficacy in Phase 1/2 Duchenne trial